Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2025-11-14 2:29 pm Purchase | 2025-09-30 | 13G | Traws Pharma, Inc. TRAW | Squadron Master Fund LP | 591,000 8.400% | 170,499 (+40.55%) | Filing History |
| 2025-10-24 4:37 pm Purchase | 2025-10-21 | 13G | NextCure, Inc. NXTC | Squadron Master Fund LP | 173,861 6.500% | 173,861 (New Position) | Filing History |
| 2025-10-15 3:11 pm Purchase | 2025-10-08 | 13G | Spruce Biosciences, Inc. SPRB | Squadron Master Fund LP | 70,000 6.600% | 70,000 (New Position) | Filing History |
| 2025-10-08 4:12 pm Purchase | 2025-10-01 | 13G | Palisade Bio, Inc. PALI | Squadron Master Fund LP | 8,250,000 8.500% | 8,250,000 (New Position) | Filing History |
| 2025-09-19 3:04 pm Purchase | 2025-09-12 | 13G | Traws Pharma, Inc. TRAW | Squadron Master Fund LP | 420,501 6.000% | 420,501 (New Position) | Filing History |
| 2025-08-14 5:22 pm Purchase | 2025-06-30 | 13G | Relmada Therapeutics, Inc. RLMD | Squadron Master Fund LP | 3,298,500 9.900% | 1,248,500 (+60.90%) | Filing History |
| 2025-05-01 4:21 pm Purchase | 2025-04-24 | 13G | Relmada Therapeutics, Inc. RLMD | Squadron Master Fund LP | 2,050,000 6.200% | 2,050,000 (New Position) | Filing History |